報價延遲最少15分鐘:2025/09/15 15:48 EDT
盤後時段
|
||||
|
-- 
|
|
|
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
4.95
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-0.14/0.22
|
|
企業價值
659.61M
|
| 資產負債 |
|
每股賬面淨值
1.84
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
482.04M
|
|
每股收益
3.61
|
|
同行比較
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
報價延遲最少15分鐘：2025/09/15 15:48 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Organogenesis Holdings Inc is a regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the advanced wound care, surgical, and sports medicine markets. The company's portfolio of regenerative medicine products in the advanced wound care category includes Apligraf, Dermagraft, PuraPly AM, CYGNUS Dual, etc., and the sports medicine products include NuShield as a surgical barrier and PuraForce as a reinforcement matrix in targeted soft tissue repairs; and Affinity, Novachor, PuraPly MZ, PuraPly AM, and PuraPly SX for management of open wounds in the surgical setting. The company operates in a single segment, that is, regenerative medicine. |
